Source: Annual Congress 2011 - Molecular biomarkers at the bedside of critically ill patients
Disease area: Respiratory critical care



Rating:

Share or cite this content

Citations should be made in the following way:
A. Torres (Barcelona, Spain). Biomarkers of early diagnosis and therapeutic response in ventilator-associated pneumonia. Annual Congress 2011 - Molecular biomarkers at the bedside of critically ill patients

Member's Comments

No comment yet.

Related content which might interest you: I like invasive techniques to define their role in the diagnosis of pneumonia and ventilator-associated pneumonia Source: Annual Congress 2009 - Diagnosis of ventilator-associated pneumonia: challenge the dogmas! Year: 2009 Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study Source: Eur Respir J 2009; 34: 1364-1375 Year: 2009 Diagnosis of ventilator-associated pneumonia Source: Annual Congress 2007 - Pulmonary infections and inflammation Year: 2007 Potential protective role of prior to diagnosis antibiotic treatment in community-acquired pneumonia: Clinical presentation and outcomes Source: Annual Congress 2011 - Antimicrobial treatment and resistance in lower respiratory tract infections Year: 2011 Inflammatory biomarkers in predicting ICU admission of severe community-acquired pneumonia (CAP) Source: Annual Congress 2011 - Pulmonary infections and sepsis Year: 2011 New approaches to the aetiological diagnosis of VAP Source: Eur Respir Mon 2011; 53: 11-23 Year: 2011 I like clinical pulmonary infection scores to define the role of clinical evaluation to diagnose pneumonia and ventilator-associated pneumonia Source: Annual Congress 2009 - Diagnosis of ventilator-associated pneumonia: challenge the dogmas! Year: 2009 Biomarkers and clinical stability in community-acquired pneumonia Source: Annual Congress 2009 - Assessment of severity in respiratory infections: severity scales and biomarkers Year: 2009 The role of inflammatory parameters in the diagnosis and management of patients with community-acquired pneumonia Source: Annual Congress 2012 - Management of pneumonia due to hospital pathogens Year: 2012 Evidence on measures for the prevention of ventilator-associated pneumonia Source: Eur Respir J 2007; 30: 1193-1207 Year: 2007 Specific treatment failure of the ventilator-associated pneumonia (VAP): predictive values Source: Eur Respir J 2006; 28: Suppl. 50, 786s Year: 2006 The impact of inflammatory-response in the outcome of trauma patients with and without ventilator-associated pneumonia Source: Eur Respir J 2004; 24: Suppl. 48, 232s Year: 2004 VAP prevention: pharmacological strategies Source: Eur Respir Mon 2011; 53: 74-82 Year: 2011 Challenges in the management of hospital-acquired pneumonia including ventilator-associated pneumonia Source: ERS Course 2018 - Respiratory Infections Year: 2018 Biomarkers as complication predictors in community-acquired pneumonia Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia Year: 2011 Diagnosis and treatment of nosocomial pneumonia in ALI/ARDS patients Source: Eur Respir J 2003; 22: 77S-83S Year: 2003 The role of procalcitonin in predicting severity and clinical course of aspiration pneumonia Source: International Congress 2015 – CAP: prognostic factors in frail patients Year: 2015 Update on therapeutic strategies in community-acquired pneumonia    Source: International Congress 2017 – PG17 Infectious disease challenges in community-acquired pneumonia and tuberculosis: improving your clinical practice Year: 2017